摘要
目的探讨联合运用达比加群酯和阿托伐他汀钙联合运用于非瓣膜性心房纤颤病人的治疗效果。方法选择我院100例住院或门诊确诊为非瓣膜性心房纤颤的病人分为两组,A组给予达比加群酯治疗,B组为在A组治疗基础上给予阿托伐他汀钙。测定凝血四项并随访患者1年,观察病人治后出血和血栓性事件的风险。结果 B组病人活化部分凝血活酶时间(APTT)、凝血酶原时间(PT)、凝血酶时间(TT)均高于A组,纤维蛋白原(FIB)低于A组,差异具有统计学意义(P<0.05);A、B组之间临床事件发生次数差异具有统计学意义(P<0.05)。结论对非瓣膜性心房纤颤病人联合运用达比加群酯和阿托伐他汀钙片较单独运用达比加群酯抗凝效果更好,出血及血栓性事件减少。
Objective To observe the effects of dabigatran etexilate and atovastatin calcium tablets for the treatment of non - valvular atrial fibrillation（NVAF）. Methods One hundred patients with NVAF were randomly divided into two groups： Group A treated by dabigatran etexilate,and group B treated by dabigatran etexilate plus atovastatin calcium tablets for one year. The 4 coagulation pa rameters were tested. The risk of the bleeding and the thromboembolism events were observed. Results The levels of activated partial thromboplastin time（APTT）, prothrombin time（PT）, thrombin time（TT） in group B were higher than in group A while the fibrinogen （FIB） level in group B was lower than that in group A（ P 〈0. 05）. There was difference in clinical incidents between two groups（ P 〈0. 05）. Conclusion Dabigatran etexilate plus atovastatin calcium tablets for the treatment of NVAF is better than dabigatran etexilate alonely,which has less events of bleeding and thromboembolism.
出处
《中西医结合心脑血管病杂志》
2016年第1期64-66,共3页
Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease
关键词
非瓣膜性心房纤颤
达比加群酯
阿托伐他汀钙片
non valvular atrial fibrillation
dabigatran etexilate
atovastatin calcium tablets
